Skip to main content
. 2019 Feb 25;10(4):545–551. doi: 10.1021/acsmedchemlett.8b00574

Figure 3.

Figure 3

Expression of PDK4 (A), CPT1A (B), and GLUT1 (C) after treatment with PPAR agonist 12a (100 μM). The enhanced activity on the gene expression is compared with the commercial compounds L165,041 (2 μM, A), GW7647 (2 μM, B), or rosiglitazone (10 μM, C) as reference positive controls.